Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $1,442,150.92 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 40,831 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $35.32, for a total value of $1,442,150.92. Following the transaction, the director now owns 193,296 shares of the company’s stock, valued at $6,827,214.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Dirk Kersten also recently made the following trade(s):

• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Trading Down 0.7 %

DYN opened at $34.62 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.45. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. The company’s fifty day moving average price is $40.41 and its two-hundred day moving average price is $33.78.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new position in Dyne Therapeutics during the 1st quarter worth $140,666,000. Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. Artal Group S.A. grew its position in Dyne Therapeutics by 24.6% in the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in Dyne Therapeutics by 10.4% in the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock valued at $42,881,000 after buying an additional 114,888 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on DYN shares. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Piper Sandler reiterated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday. JPMorgan Chase & Co. boosted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.